- Market Capitalization, $K 186,744
- Shares Outstanding, K 23,198
- Annual Sales, $ 90 K
- Annual Income, $ -39,910 K
- 60-Month Beta 4.75
- Price/Sales 2,255.06
- Price/Cash Flow N/A
- Price/Book 2.06
|Period||Period Low||Period High||Performance|
| || |
-0.79 (-8.94%)since 09/18/19
| || |
-3.82 (-32.18%)since 07/18/19
| || |
+0.76 (+10.43%)since 10/18/18
Chicago, Illinois--(Newsfile Corp. - October 15, 2019) - Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), will be presenting at the 5th Benzinga Cannabis Capital Conference in Chicago October 22-23 before...
- FinancialBuzz.com News Commentary
The U.S. Drug Enforcement Agency recently announced plans to expand cannabis research after a prolonged delay. The DEA said it hopes to receive a variety of compelling research about marijuana after the...
Church & Dwight Co. (CHD)
FinancialBuzz.com News Commentary
Cannabis has been used for medicinal purposes for centuries, but despite the therapeutic benefits of the plant, international regulators ultimately deemed it unsafe for the public due to its marijuana...
Zynerba Pharmaceuticals (ZYNE) closed at $7.26 in the latest trading session, marking a -1.43% move from the prior day.
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...
Cannabis (or marijuana) based medical products have the potential to become the next booming industry.
Pomerantz LLP is investigating claims on behalf of investors of Zynerba Pharmaceuticals ("Zynerba" or the "Company") (NASDAQ: ZYNE). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org...